dihydroxyphenylalanine has been researched along with Muscle Rigidity in 28 studies
Dihydroxyphenylalanine: A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific.
dopa : A hydroxyphenylalanine carrying hydroxy substituents at positions 3 and 4 of the benzene ring.
Muscle Rigidity: Continuous involuntary sustained muscle contraction which is often a manifestation of BASAL GANGLIA DISEASES. When an affected muscle is passively stretched, the degree of resistance remains constant regardless of the rate at which the muscle is stretched. This feature helps to distinguish rigidity from MUSCLE SPASTICITY. (From Adams et al., Principles of Neurology, 6th ed, p73)
Excerpt | Relevance | Reference |
---|---|---|
"Twenty-seven patients with Parkinson's disease participated in a double-blind crossover trial of L-dopa and amantadine." | 1.25 | Interactions of L-dopa and amantadine in patients with Parkinsonism. ( Cox, B; Danta, G; Schnieden, H; Yuill, GM, 1973) |
"Six patients diagnosed as Parkinson's disease on a clinical basis alone are described, and their response to L-dopa and to alpha methyl dopa hydrazine (MK 486) and L-dopa." | 1.25 | An analysis of six patients with Parkinson's disease who have been unresponsive to L-dopa therapy. ( Mones, RJ, 1973) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 26 (92.86) | 18.7374 |
1990's | 2 (7.14) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Budakova, NN | 1 |
Otsuka, M | 1 |
Ichiya, Y | 1 |
Kuwabara, Y | 1 |
Hosokawa, S | 1 |
Sasaki, M | 1 |
Yoshida, T | 1 |
Fukumura, T | 1 |
Masuda, K | 1 |
Kato, M | 1 |
Sawle, GV | 1 |
Brooks, DJ | 1 |
Marsden, CD | 2 |
Frackowiak, RS | 1 |
Bird, ED | 1 |
Iversen, LL | 1 |
Steg, G | 1 |
McLellan, DL | 1 |
Bernheimer, H | 1 |
Birkmayer, W | 2 |
Hornykiewicz, O | 1 |
Jellinger, K | 1 |
Seitelberger, F | 1 |
Linauer, W | 1 |
Mentasti, M | 1 |
Riederer, P | 1 |
Sano, I | 1 |
Taniguchi, K | 1 |
Gerstendbrand, F | 1 |
Gründig, E | 1 |
Musiol, A | 1 |
Ngai, SH | 1 |
Velasco, F | 1 |
Velasco, M | 1 |
Gehlen, W | 1 |
Eisenlohr, JJ | 1 |
Rosati, G | 1 |
Agnetti, V | 1 |
Mura, F | 1 |
Granieri, E | 1 |
Groneberg, P | 1 |
Struppler, A | 1 |
Wycis, HT | 1 |
Andrews, CJ | 1 |
Burke, D | 1 |
Cox, B | 1 |
Danta, G | 1 |
Schnieden, H | 1 |
Yuill, GM | 1 |
Mones, RJ | 1 |
Kofman, OS | 1 |
Van Buren, JM | 1 |
Li, CL | 1 |
Shapiro, DY | 1 |
Henderson, WG | 1 |
Sadowsky, DA | 1 |
Wand, P | 1 |
Kuschinsky, K | 1 |
Sontag, KH | 1 |
Lhermitte, F | 1 |
Chain, F | 1 |
Escourolle, R | 1 |
Chedru, F | 1 |
Guilleminault, C | 1 |
Francoual, M | 1 |
Lieberman, AN | 1 |
Chase, TN | 1 |
Woods, AC | 1 |
Glaubiger, GA | 1 |
Parkes, JD | 1 |
Rees, JE | 1 |
Curzon, G | 1 |
Kantamaneni, BD | 1 |
Knill-Jones, R | 1 |
Akbar, A | 1 |
Das, S | 1 |
Kataria, M | 1 |
Bauer, RB | 1 |
McHenry, JT | 1 |
De Vito, AJ | 1 |
Riklan, M | 1 |
Misiak, H | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Adenosine A2A Blockade With KW-6002 in Parkinson's Disease[NCT00006337] | Phase 2 | 16 participants | Interventional | 2000-10-31 | Completed | ||
Effect of Antiglutamatergic Treatment in Parkinson's Disease[NCT00013624] | Phase 2 | 20 participants | Interventional | 2001-03-31 | Completed | ||
Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's Disease[NCT00006077] | Phase 2 | 50 participants | Interventional | 2000-08-31 | Completed | ||
Effect of Serotoninergic Treatment in Parkinson's Disease[NCT00009048] | Phase 2 | 30 participants | Interventional | 2001-01-31 | Completed | ||
Levetiracetam Treatment of L-dopa Induced Dyskinesias[NCT00076674] | Phase 2 | 40 participants | Interventional | 2004-01-31 | Completed | ||
AMPA Receptor Blockade With LY300164 in the Treatment of Parkinson's Disease[NCT00004576] | Phase 2 | 20 participants | Interventional | 2000-02-29 | Completed | ||
Prognostic Value of FP-CIT-SPECT in Patients With Parkinson´s Disease[NCT01038310] | 25 participants (Actual) | Observational | 2010-01-31 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
3 reviews available for dihydroxyphenylalanine and Muscle Rigidity
Article | Year |
---|---|
Pathological aspects on Parkinson's syndrome.
Topics: Animals; Basal Ganglia; Basal Ganglia Diseases; Central Nervous System; Chlorpromazine; Corpus Stria | 1972 |
[Current treatment of Parkinson syndrome with L-dopa].
Topics: Administration, Oral; Blood-Brain Barrier; Dihydroxyphenylalanine; Dopa Decarboxylase; Drug Synergis | 1972 |
Parkinsonism, levodopa, and anesthesia.
Topics: Amantadine; Anesthesia; Animals; Apomorphine; Benperidol; Blood-Brain Barrier; Brain; Cardiovascular | 1972 |
5 trials available for dihydroxyphenylalanine and Muscle Rigidity
Article | Year |
---|---|
[2-year experiences with a combination treatment of Parkinsonism with L-dopa and a decarboxylase inhibitor (Benserazid, Ro 4-4602)].
Topics: Benserazide; Carboxy-Lyases; Clinical Trials as Topic; Dermatitis, Seborrheic; Dihydroxyphenylalanin | 1974 |
A quantitative evaluation of the effects of L-dopa on Parkinson's disease.
Topics: Arm; Clinical Trials as Topic; Dihydroxyphenylalanine; Humans; Movement; Movement Disorders; Muscle | 1973 |
[Treatment of Parkinsonic syndrome with levo-Dopa. Case reports].
Topics: Arteriosclerosis; Clinical Trials as Topic; Dihydroxyphenylalanine; Drug Evaluation; Female; Humans; | 1974 |
Parkinson disease treated with a suspected dopamine receptor agonist.
Topics: Adult; Aged; Amantadine; Aromatic Amino Acid Decarboxylase Inhibitors; Benztropine; Dihydroxyphenyla | 1974 |
Comparison of amantadine, placebo, and levodopa in Parkinson's disease.
Topics: Aged; Amantadine; Dihydroxyphenylalanine; Evaluation Studies as Topic; Female; Humans; Male; Middle | 1974 |
20 other studies available for dihydroxyphenylalanine and Muscle Rigidity
Article | Year |
---|---|
[Spontaneous generation of locomotor rhythmicity].
Topics: Animals; Brain Mapping; Brain Stem; Cats; Decerebrate State; Dihydroxyphenylalanine; Electromyograph | 1980 |
Differences in the reduced 18F-Dopa uptakes of the caudate and the putamen in Parkinson's disease: correlations with the three main symptoms.
Topics: Adult; Aged; Caudate Nucleus; Dihydroxyphenylalanine; Female; Fluorine Radioisotopes; Humans; Male; | 1996 |
Corticobasal degeneration. A unique pattern of regional cortical oxygen hypometabolism and striatal fluorodopa uptake demonstrated by positron emission tomography.
Topics: Aged; Animals; Apraxias; Brain Diseases; Cerebral Cortex; Corpus Striatum; Dihydroxyphenylalanine; E | 1991 |
Letter: Rigidity in Huntington's chorea.
Topics: Basal Ganglia; Brain; Dihydroxyphenylalanine; Dopamine; Humans; Huntington Disease; Muscle Rigidity; | 1974 |
Dynamic spindle reflexes and the rigidity of Parkinsonism.
Topics: Adult; Aged; Dihydroxyphenylalanine; Electric Stimulation; Female; Humans; Male; Middle Aged; Muscle | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Topics: Aged; Autopsy; Basal Ganglia; Benzoates; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; D | 1973 |
[L-5-hydroxytryptophan(L-5-HTP) therapy of Parkinson's disease. 2].
Topics: 5-Hydroxytryptophan; Adult; Aged; Depression; Dihydroxyphenylalanine; Female; Humans; Male; Middle A | 1972 |
[Quantitative rigor determination in Parkinson's disease. Myo-integration for therapy control of L-Dopa in combination with a decarboxylase inhibitor (Ro 8-0576)].
Topics: Aged; Benserazide; Carboxy-Lyases; Dihydroxyphenylalanine; Drug Evaluation; Electromyography; Humans | 1974 |
[The therapeutic effect of L-dopa].
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Asthma; Brain; Dihydroxyphenylalanine; Dopamine; Human | 1972 |
The role of a dihydromorphanthridine derivative in Parkinson's patients treated with L-dopa. A preliminary report.
Topics: Antiparkinson Agents; Dibenzazepines; Dihydroxyphenylalanine; Dimethylamines; Drug Synergism; Evalua | 1972 |
Quantitative study of the effect of L-dopa and phenoxybenzamine on the rigidity of Parkinson's disease.
Topics: Aged; Dihydroxyphenylalanine; Electromyography; Female; Humans; Male; Middle Aged; Muscle Contractio | 1973 |
Interactions of L-dopa and amantadine in patients with Parkinsonism.
Topics: Amantadine; Dihydroxyphenylalanine; Drug Interactions; Evaluation Studies as Topic; Female; Homovani | 1973 |
An analysis of six patients with Parkinson's disease who have been unresponsive to L-dopa therapy.
Topics: Aged; Carbidopa; Diagnosis, Differential; Dihydroxyphenylalanine; Evaluation Studies as Topic; Femal | 1973 |
A therapeutic paradox? Combined treatment of Parkinson's disease with levodopa and methyldopa.
Topics: Dihydroxyphenylalanine; Drug Synergism; Evaluation Studies as Topic; Female; Follow-Up Studies; Huma | 1973 |
A qualitative and quantitative evaluation of parkinsonians three to six years following thalamotomy.
Topics: Dihydroxyphenylalanine; Evaluation Studies as Topic; Follow-Up Studies; Humans; Motor Skills; Muscle | 1973 |
Morphine-induced muscular rigidity in rats.
Topics: Animals; Apomorphine; Dihydroxyphenylalanine; Dopamine; Dose-Response Relationship, Drug; Electromyo | 1973 |
[A further case of tetanus-like contracture distinct from the stiff man syndrome. Pharmacological and neuropathological study of a case of predominantly spinal encephalomyelitis].
Topics: Aged; Carbamazepine; Contracture; Diazepam; Dihydroxyphenylalanine; Electromyography; Encephalomyeli | 1973 |
Parkinson's disease: a clinical review.
Topics: Adult; Aged; Brain Diseases; Bulbar Palsy, Progressive; Dementia; Diagnosis, Differential; Dihydroxy | 1974 |
Parkinson's disease, cerebral arteriosclerosis, and senile dementia. Clinical features and response to levodopa.
Topics: Aged; Dementia; Dihydroxyphenylalanine; Electroencephalography; Female; Gait; Homovanillic Acid; Hum | 1974 |
Effect of L-dopa on electromyograph and heart rate of parkinsonians.
Topics: Aged; Arousal; Dihydroxyphenylalanine; Electromyography; Female; Functional Laterality; Heart Rate; | 1972 |